posted on October 07, 2010 16:05
GSK R&D has announced the start of four new academic collaborations with Singapore-based scientists and GSK’s global drug discovery network as the first step in a long-term plan to seek alliances with scientific experts in the country.
The collaborations address challenges in ophthalmology, regenerative medicine, and neurodegeneration. They focus on early stage research of mutual interest to GSK and the researchers, and were put in place just eight months after a GSK symposium introduced the Academic Centre for Excellence (ACE) – a virtual community established by GSK to promote partnering with academics in Singapore on drug discovery projects.ACE's inaugural 4 projects, unveiled at the Awards Ceremony today, were:
- Epigenetic control of adipogenesis - Dr Xu Feng (Singapore Institute for Clinical Sciences, A*STAR)
- Development of optogenetic and electrophysiological animal models of evaluation for pharmacological enhancement of neural stem cell function and differentiation - Dr Gavin Dawe (National University of Singapore, School of Medicine)
- Functional integration of endogenous and implanted stem cells into the existing central nervous system - Dr Eyleen Goh (Duke-NUS, Graduate Medical School)
- Retinal vascular signs as novel biomarkers of dementia - Dr Wong Tien Yin, Dr Carol Cheung (Singapore Eye Research Institute) and Dr Christopher Chen (National University Hospital)
To read chairman's speech, click here